LDS/Medical Tests/Polymerase ɛ (POLE) Gene Mutation Analysis

Polymerase ɛ (POLE) Gene Mutation Analysis

DNA replication fidelity is safeguarded by several DNA polymerases that not only synthesize DNA but also perform proofreading and repair. One such polymerases is the Polymerase ɛ encoded by the POLE gene and is essential for proofreading of newly added nucleotides in the 3’→5’ direction and participates in nucleotide excision and base excision repair pathways. Pathogenic somatic or germline mutations in POLE can disrupt this proofreading activity, leading to an accumulation of mutations, genomic instability, and tumorigenesis.

Somatic POLE mutations have been identified in colorectal, endometrial, ovarian, pancreatic cancers, and glioblastomas. Germline mutations confer familial cancer predisposition, particularly for colorectal cancer and brain tumors. Among all cancers, POLE mutations are most prevalent in endometrial cancer, occurring in approximately 7–10% of cases.

POLE-mutated tumors often exhibit an 'ultramutated' phenotype characterized by a very high tumor mutational burden (TMB), distinct histologic features, and favorable progression-free survival compared to other molecular subtypes. Hotspot mutations such as P286R and V411L in the exonuclease domain are the most common and clinically significant. Recognition of POLE mutations has prognostic and therapeutic implications, as these tumors are highly immunogenic and may respond well to immune checkpoint inhibitors.

  • Aid in the diagnosis of endometrial and colorectal cancers
  • Identification of patients with ultramutated tumors who may have improved prognosis
  • Assist in therapeutic decision-making, particularly for immunotherapy eligibility
  • Aid in identifying individuals and families at increased hereditary cancer risk

A positive result indicates the presence of clinically significant POLE mutation(s). This suggests an increased risk of cancer development and may identify tumors with favorable prognosis and potential benefit from immunotherapy.

A negative result indicates the absence of detectable pathogenic POLE mutations. However, it does not exclude the possibility of cancer, as other molecular alterations may be involved.

Negative (No pathogenic POLE mutations detected)

Next-generation sequencing (NGS) targeting the exonuclease domain of POLE and relevant cancer-associated regions.

Formalin-fixed paraffin-embedded (FFPE) tumor tissue.

Stability

FFPE is stable for longer in Ambient temperature.

Microsatellite instability (MSI) analysis, mismatch repair (MMR) protein immunohistochemistry (MLH1, MSH2, MSH6, PMS2), CA-125, Pap smear cytology (for gynecologic cancers), and tumor mutational burden (TMB) testing.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login